Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

SIMPLE SUMMARY: Patients with multiple myeloma (MM) who become refractory to three or more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them, drugs directed against the BCMA antigen expressed in plasma cells are very appealing. Belantamab-mafodotin (belamaf) is the...

Descripción completa

Detalles Bibliográficos
Autores principales: de la Rubia, Javier, Alonso, Rafael, Clavero, María Esther, Askari, Elham, García, Alfonso, Antón, Cristina, Fernández, Margarita, Escalante, Fernando, García, Ana, Rios-Tamayo, Rafael, Conesa, Venancio, Bermúdez, María Arancha, Merchán, Beatriz, Velasco, Alberto E., Blanchard, María Jesús, Sampol, Antonia, Gainza, Eukene, Hernández, Prisma Montserrat, Alegre, Adrián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251953/
https://www.ncbi.nlm.nih.gov/pubmed/37296925
http://dx.doi.org/10.3390/cancers15112964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251953/
https://www.ncbi.nlm.nih.gov/pubmed/37296925
http://dx.doi.org/10.3390/cancers15112964

Ejemplares similares